Hepatic CCN2 may aid the assessment of NASH fibrosis severity and, together with pro-fibrogenic EVs, is a therapeutic target for reducing NASH fibrosis. This evidence concerns the gene CCN2 and metabolic dysfunction-associated steatohepatitis.